Mayor Scott unveils new plan to help tackle Baltimore City's vacant home crisis
The plan, titled Bmore F.A.S.T. (Facilitating Approvals and Streamlining Timelines), involves a $3 billion investment. The goal is to speed up the property development process in the city, while maintaining safety standards and community input, according to the mayor.
Central to the plan is the creation of a new Director of Permitting and Development Services position within the mayor's office. The role will coordinate across agencies to eliminate bottlenecks in the development process.
"The stakes couldn't be higher," Scott said. "Our city faces both a housing crisis and commercial corridor challenges that require immediate action."
For developers, the plan includes a new e-permits platform, self-certification options for qualified professionals, simplified developer agreements for public right-of-way work, and a utility coordination program to align with major service providers.
Operational improvements include a performance management system for development services, proactive clearing of liens on city-acquired properties, and reorganizing the Office of Zoning Administrator within the Department of Planning.
In the announcement, Scott cited his administration's first-term progress, including a 16.5% reduction in vacant properties and the creation of over 9,000 affordable housing units. The reforms are designed to support the Bmore FAST plan to address 37,500 vacant properties over the next 15 years.
To execute the plan, the city is establishing the Bmore F.A.S.T. Advisory Group made up of developers, contractors, architects, and community representatives will guide implementation.
The full plan is available at the City of Baltimore website.
Baltimore works to tackle the vacant housing crisis
In December, the Baltimore City Council passed a bill to increase the property tax for vacant homes, to encourage homeowners to take better care of their property.
In December 2024, according to Councilwoman Odette Ramos, Baltimore City owns less than 1,000 vacant properties, and thousands more are falling apart or designated as uninhabitable.
As of early October 2024, only 3,600 properties qualified for the tax rate increase, though that number is expected to increase under the recently passed bill.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
3 hours ago
- Forbes
Tour Championship's Future At East Lake In Question
The PGA Tour comes to a conclusion this week at the Tour Championship at East Lake Golf Club in Atlanta, GA, and there are rumors the host site could be changing. East Lake has hosted the Tour Championship since 2004, when its primary sponsor, Coca-Cola, urged the Tour to move away from its previous rotating site, Champions Golf Club in Houston, TX. Since its inception in 1987, the Tour Championship has been held at eight venues, including Pinehurst No. 2, The Olympic Club, Pebble Beach, Oak Hill, Harbour Town, and Southern Hills. 'It's been discussed,' said Adam Scott, a player director on the PGA Tour Policy Board. 'We've questioned everything at some point. I couldn't tell you contractually how long we're tied there, but East Lake is where it's at.' Title sponsors of the PGA Tour Playoff series may have influenced the location decisions. FedEx, headquartered in Memphis, TN and sponsor of the FedEx St. Jude Championship, helped turn what was once a rotating event into a fixed one. Previously, the Westchester Classic (later known as The Barclays) was held at Westchester Country Club in New York from 1967 to 2007 before rotating between venues along the East Coast. The BMW Championship, formerly the Western Open, also provides a case study. For decades, the event was tied to Chicago: played at Butler National from 1974 to 1990 and then at Cog Hill from 1991 to 2006. Its proximity to the Western Golf Association's headquarters played a major role. A rebrand and new title sponsor later, the BMW Championship became a rotating event, ironically no longer confined to the 'West.' 'I don't hear fans say it is an exciting golf course to watch golf,' professional golfer Peter Malnati said of East Lake. 'I know it does a lot for the community and that's very important, but I think it would be cool for our biggest trophy to be given away at a course that really excites fans. But there are a lot of things that have to be done in the right way to make that happen. I think East Lake works really hard to be an amazing host. I'd love to see our fans be excited about where we play the Tour Championship in addition to the tournament itself.' The current contract with East Lake Golf Club ends in 2027. With the BMW Championship already rotating and frequent player feedback about the heat and humidity in Georgia in August, the Tour Championship could be next to move. SSG, with its $1.5 billion investment into the PGA Tour, might consider adding another stop in its headquarters city, Orlando, FL, though that too would be another steamy summer site. Jason Day has voiced support for rotating playoff venues, starting with the FedEx St. Jude Championship in Memphis, where he struggles at TPC Southwind. 'I'm like, when can we leave?' Day said. 'But I definitely think we should move around a bit, yeah, for sure.' Several major metropolitan areas in the U.S. currently lack regular PGA Tour stops but could provide fresh tests if the playoff events rotated. Cities like Chicago, Denver, Boston, New York, Philadelphia, Indianapolis, Washington, D.C., St. Louis, Seattle, Salt Lake City, Oklahoma City, and Portland could all offer championship caliber venues. Cooler climates in the Midwest and Pacific Northwest would also give players a more comfortable environment to compete in. Normal Tour venues must have facilities for fields of around 150 players, but the reduced playoff fields require less dining, practice, and locker space. However, infrastructure for media, grandstands, and broadcast technology will still be critical factors in venue selection. With East Lake's contract expiring, a new investor in the mix, and shifting sponsor priorities, both the Tour Championship and the FedEx St. Jude Championship could soon be on the move.
Yahoo
7 hours ago
- Yahoo
Black Hills and NorthWestern to merge into company with $7.8bn market cap
Black Hills and the NorthWestern Energy Group have entered a definitive agreement for an all-stock, tax-free merger that will establish a regional electric and natural gas utility company with a pro forma market capitalisation of $7.8bn. The combined company will serve more than two million customers across eight US states. The proposed combination would result in a total enterprise value of $15.4bn based on both companies' stock prices as of 18 August 2025. NorthWestern shareholders will receive a fixed exchange ratio of 0.98 shares of Black Hills per share owned at closing, representing a 4% premium based on average stock prices since discussions began in March 2025. Black Hills investors will own 56% while NorthWestern shareholders will hold 44% of the combined company on a fully diluted basis. Black Hills president and CEO Linn Evans stated: 'We are excited to bring our two highly complementary companies together to create significant long-term value for customers, employees, shareholders and the communities we serve. Our future success will be driven equally by the people, assets and capabilities of both organisations. 'The combined company will have greater scale and financial strength to consistently deliver for customers across our service territories and invest at the pace and scale that today's energy transformation demands.' The new board for the merged entity will comprise six directors from Black Hills and five from NorthWestern, with headquarters in Rapid City, South Dakota. Joint investment plans from 2025 to 2029 exceed $7bn, focusing on critical infrastructure for electricity and natural gas to cater to growing energy needs while maintaining competitive rates for consumers. The merged company targets an earnings per share (EPS) growth rate between 5% and 7% annually, which is higher than either company's current standalone projections and anticipates accretive EPS in the first year after closing. The transaction will be completed within 12 to 15 months, pending customary conditions. This includes obtaining clearance under the Hart-Scott-Rodino Act, securing shareholder approvals, and regulatory consents. These approvals will involve commissions in the three states where both companies currently operate, Montana, Nebraska, South Dakota, and in Arkansas if needed, as well as Federal Energy Regulatory Commission endorsement. NorthWestern Energy president and CEO Brian Bird stated: 'Our merger with Black Hills will create a premier regional regulated utility company with a larger, more resilient platform consistent with mid-cap peers. 'Together, we will be better positioned to meet rising demand, accelerate investment in energy and grid infrastructure, and support customers and communities through a rapidly evolving energy landscape.' Goldman Sachs acted as financial advisor for Black Hills, with Faegre Drinker Biddle & Reath providing legal counsel. While Greenhill advised NorthWestern financially, alongside Morgan Lewis & Bockius handling legal matters. In December 2024, NorthWestern Energy acquired a stake in the North Plains Connector HVDC (high-voltage direct current) transmission line. The 3GW line will extend 420 miles (676km), connecting Bismarck, North Dakota, to Colstrip, Montana. "Black Hills and NorthWestern to merge into company with $7.8bn market cap" was originally created and published by Power Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Business Wire
13 hours ago
- Business Wire
Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform
SANTA MONICA, Calif. & PHILADELPHIA--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350 million. This acquisition complements Kite's expertise in cell therapy by incorporating Interius's integrating in vivo platform. This approach enables the generation of CAR T-cells directly within the patient's body and may offer a more durable and long-lasting therapeutic effect by inserting DNA into the patient's genome. Unlike traditional CAR T therapies that require cell harvesting, engineering and reinfusion, Interius's innovative, off-the-shelf yet personalized approach is designed to be delivered via a single intravenous infusion, eliminating the need for preconditioning chemotherapy and complex cell processing. 'In vivo therapy is a promising frontier with the potential to transform how we approach treating patients, shifting to more accessible and scalable solutions,' said Cindy Perettie, Executive Vice President of Kite. 'By combining Interius's teams and their novel platform with Kite's deep expertise and footprint in cell therapy research, development and manufacturing, we aim to advance best-in-class in vivo therapies to bring them to patients more efficiently.' The modular architecture of Interius's platform allows for rapid adaptation across disease states and scale of manufacturing, enabling the potential to expand access to cell therapies for patients who previously could not benefit from them, particularly those with rapidly progressing disease. 'This marks a pivotal step for Interius and the future of in vivo therapy, which has the potential to reduce treatment timelines, broaden access to care and improve outcomes for patients with aggressive or advanced disease,' said Phil Johnson, President and CEO, Interius BioTherapeutics. 'With the addition of Kite's deep expertise and global infrastructure, we're well-positioned to move quickly into multiple therapeutic areas, expand access to cell therapies and deliver meaningful innovation to patients.' Interius's team and operations will integrate into Kite's established research team, creating a center of excellence in Philadelphia to accelerate the development of next-generation in vivo therapies. Terms of the Agreement Under the terms of the acquisition agreement with Interius, Kite will acquire all of the outstanding share capital of Interius for a total of $350 million in cash consideration, subject to customary adjustments, which is payable at closing. This transaction with Interius is expected to reduce Gilead's GAAP and non-GAAP 2025 EPS by approximately $0.23-$0.25. Closing of the transaction is subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. TD Cowen is acting as exclusive financial advisor to Kite and Evercore is serving as exclusive financial advisor to Interius. About Kite Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on achieving cures with cell therapy. With a global cell therapy footprint, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply and commercial product manufacturing. For more information on Kite, please visit About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif. Gilead acquired Kite in 2017. About Interius BioTherapeutics Interius BioTherapeutics is a clinical stage biotechnology company engineering targeted, programmable vectors for the precision delivery of genetic medicines to treat an array of challenging diseases in oncology, autoimmunity and beyond. Leveraging a proprietary platform, Interius has created a differentiated off-the-shelf therapeutic modality designed for broad patient access. The Company's lead programs aim to overcome the current limitations of ex vivo chimeric antigen receptor (CAR) T-cell therapy by creating therapeutic CAR cells directly in the patient's body, avoiding preconditioning chemotherapy, manufacturing bottlenecks and high costs. For more information, visit and follow us on LinkedIn. Gilead Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the ability of the parties to complete the transaction in a timely manner or at all; the possibility that various closing conditions for the transaction may not be satisfied or waived, including the possibility that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; uncertainties relating to the timing or outcome of any filings and approvals relating to the transaction; difficulties or unanticipated expenses in connection with integrating the companies, including the effects of the transaction on relationships with employees, other business partners or governmental entities; the risk that Gilead and Kite may not realize the expected benefits of this transaction; the ability of Gilead and Kite to advance their product pipeline and successfully commercialize product candidates following the acquisition; the ability of the parties to initiate and complete clinical trials involving such product candidates in the currently anticipated timelines or at all; the possibility of unfavorable results from one or more of such trials involving such product candidates; uncertainties relating to regulatory applications and related filing and approval timelines, including the risk that FDA may not approve any such product candidates in the anticipated indications or on the timelines or at all, and any marketing approvals, if granted, may have significant limitations on its use; any assumptions underlying any of the foregoing. These and other risks, uncertainties and other factors are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Kite, and Gilead and Kite assume no obligation and disclaim any intent to update any such forward-looking statements.
